Clinical trials – Stem cells and Autism
| Type of trial | Number and type of cells transplanted/source | Duration | Primary outcomes | Reference |
|---|---|---|---|---|
| Autologous, open-label | 8.19 × 107 mononuclear cells/bone marrow | 26 months | Safety Improvements in cognitive and social tasks Improvement in hypoperfused brain areas | 88 |
| Allogenic, nonrandomized, open-label, single-center Phase I/II trial, combined transplantation | 2 × 106/kg mononuclear cells/cord blood and 1 × 106/kg mesenchymal stem cells/umbilical cord | 24 weeks | Safety Improvements in stereotypic behaviors and lethargy/social withdrawal | 91 |
| Allogenic, open-label, single center | 30 × 106/mL fetal stem cells/fetus | 12 months | Safety Improvement in cognitive ability, behaviors, sociabilityImprovements in immune functions | 37 |
| Autologous, randomized, blinded, placebo- controlled | Umbilical cord | 24 weeks | Safety No improvements in symptoms | 93 |
| Autologous, Phase I, single-center, open-label | Umbilical cord | 12 months | Safety Improvement in socialization, communication, and adaptive behavior | 94 |
